WO2018101798A1 - Extrait soluble dans l'eau de l'artemisia capillaris, son utilisation et son procédé de préparation - Google Patents

Extrait soluble dans l'eau de l'artemisia capillaris, son utilisation et son procédé de préparation Download PDF

Info

Publication number
WO2018101798A1
WO2018101798A1 PCT/KR2017/014030 KR2017014030W WO2018101798A1 WO 2018101798 A1 WO2018101798 A1 WO 2018101798A1 KR 2017014030 W KR2017014030 W KR 2017014030W WO 2018101798 A1 WO2018101798 A1 WO 2018101798A1
Authority
WO
WIPO (PCT)
Prior art keywords
gastric
mucosal
gastrointestinal
gastric mucosal
extract
Prior art date
Application number
PCT/KR2017/014030
Other languages
English (en)
Korean (ko)
Inventor
이효종
윤현주
Original Assignee
인제대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인제대학교 산학협력단 filed Critical 인제대학교 산학협력단
Publication of WO2018101798A1 publication Critical patent/WO2018101798A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health

Definitions

  • the present invention is a water-soluble extract of Artemisia capillaris , a composition for the prevention or improvement of gastrointestinal diseases containing the same, more specifically mucosal damage gastrointestinal caused by excessive gastric acid and stress through the maintenance, protection and regeneration of the gastrointestinal mucosa system
  • the present invention relates to a food composition and a pharmaceutical composition containing a water-soluble phosphorus mugwort extract having an effect of preventing or ameliorating related diseases.
  • Injin mugwort has been used for fatty liver, chronic hepatitis, gastrointestinal diseases, constipation, jaundice, neuralgia, etc., and is effective for alcohol drinking and fat accumulation inhibitory people and liver disease, and anti-inflammatory, diuretic, gallstone inhibitory effects are known.
  • hemostatic effect is a blood bleeding (nose blood), bleeding (blood vomiting), bleeding (blood to the anus). It is used to treat bleeding from the womb, and as a first aid to reduce pain.
  • leaf extracts have been reported to have antioxidant and NF- ⁇ B inhibitory effects and to suppress gastric damage and inflammation based on them.
  • the prevention of gastric damage due to the antioxidant effects of PGE2 and GSH in NSAIDS gastric injury model (World J Gastroenterol 2005; 11 (47): 7450-7456), and the antioxidant activity of PGE2 and GSH in chronic reflux gastritis model Effect of prevention of gastric injury due to effects (World J Gastroenterol 2005; 11 (47): 7430-7435), increased secretion of Ghrelin, a hormone with gastric protective effect in acute alcoholic gastritis model (Gut and liver 2011; 5 1): 52-56), reducing IL-8 and CCL20 through p38 inhibition and NF- ⁇ B inhibition in a TNF- ⁇ mediated gastric epithelial inflammation model (World J Gastroenterol 2006; 12 (30): 4850-4858). ) has been reported.
  • the leaf extracts and the extract of Injin mugwort have an effect of improving acute gastritis or bacterial gastritis through suppression of the inflammatory response.
  • the effectiveness of the extracts of leaf or wormwood in preventing or improving gastrointestinal mucosa have been no reports about the effectiveness of the extracts of leaf or wormwood in preventing or improving gastrointestinal mucosa.
  • Another object of the present invention to provide a food composition for the prevention or improvement of mucosal damage gastrointestinal diseases.
  • Another object of the present invention to provide a pharmaceutical composition for the prevention or treatment of mucosal damage gastrointestinal diseases.
  • composition for the prevention or improvement of gastric mucosal damaging gastrointestinal diseases containing Artemisia capillaris water-soluble extract.
  • composition for the prevention or improvement of gastric mucosal damaging gastrointestinal disease of 3 above which prevents or inhibits mucosal damage caused by gastritis or gastric ulcer caused by gastric acid, ethanol, stress or a combination thereof.
  • composition for the prevention or improvement of gastric mucosal damage gastrointestinal disease of 3 above which inhibits or improves gastric mucosal damage through increased expression of gastric mucosal proteins or mucosal immune factors.
  • the gastric mucosal protein or mucosal immune factor is MUC5AC, MUC6, rPigr, TFF1, TFF2 and TFF3 composition for the prevention or improvement of gastric mucosal damaging gastrointestinal disease of the above 7, wherein at least one selected from the group consisting of.
  • composition for the prevention or improvement of gastric mucosal damaging gastrointestinal disease of 3 above which inhibits or improves gastric mucosal damage by inhibiting inflammatory cytokines, inhibiting the production of lipid peroxides, or increasing antioxidant enzyme activity.
  • a pharmaceutical composition for preventing or treating gastric mucosal damaging gastrointestinal diseases containing Artemisia capillaris water-soluble extract.
  • gastric mucosal protein or mucosal immune factor is at least one selected from the group consisting of MUC5AC, MUC6, rPigr, TFF1, TFF2, and TFF3.
  • Concentration of the concentrate from which the precipitate was removed was second concentrated until the water content was 55 ⁇ 5% to obtain an Artemisia capillaris aqueous extract;
  • Injinssuk (Artemisia capillaris) method for producing an aqueous extract containing.
  • Aqueous extract of Artemisia capillaris is a gastric mucosal mucin protein (MUC6, MUC5AC), including the major regulatory factors (TFF1, 2, 3) of the gastrointestinal mucosa system.
  • MUC6, MUC5AC gastric mucosal mucin protein
  • TNF1, 2, 3 the major regulatory factors of the gastrointestinal mucosa system.
  • rPigr mucosal immune related factors
  • SOD antioxidant enzymes
  • MDA lipid peroxides
  • Phosphorus erythema extracts have the effect of preventing and inhibiting mucosal damage to gastritis / gastric ulcer induced by hydrochloric acid-ethanol by increasing the expression of key regulatory factors of the gastrointestinal mucosal system, thus protecting the gastrointestinal tract through promoting mucosal production, It can be used as natural medicines, health functional foods, functional drinks, etc. to prevent gastric damage caused by stress or stomach acid. It also prevents and treats gastritis and gastric ulcers, which can be caused mainly by eating spicy, spicy foods, and excessive gastric acid, indigestion, and gas bloating caused by frequent drinking or decreased mucosa following NSAIDs.
  • Injin mugwort extract is applicable to the prevention and treatment of gastric cancer and colon cancer through the increase of TFF3.
  • Figure 1 is a result confirming the effect of the extract of A. erysipelas water soluble extract (AEAC) in mast cell degranulation in the mast cells induced by compound 48/80.
  • AEAC erysipelas water soluble extract
  • Figure 2 is a result confirming the inhibitory effect of inflammatory cytokine by the water soluble extract (AEAC) in mast cells induced by PMA and A23187.
  • AEAC water soluble extract
  • Figure 3 is a result confirming the inhibitory effect of inflammatory cytokine by L. aeruginosa water-soluble extract (AEAC) in LPS-induced macrophages.
  • AEAC L. aeruginosa water-soluble extract
  • Figure 4 is a result of confirming the neutralizing ability of calcium carbonate, phosphorus mugwort soluble extract (AEAC), licorice extract (AC) and leaf extract (AEAA).
  • Figure 5 is a result confirming the effect of H. ethanol-induced acute gastritis / gastric ulcer animal model influx of the extract of AJC in the production or secretion of histamine in serum.
  • Figure 6 is a result confirming the gastric mucosa protective effect by the water soluble extract (AEAC) in acute gastritis / gastric ulcer animal model induced by HCl / ethanol.
  • AEAC water soluble extract
  • Figure 7 shows the results of confirming the effect of increasing the amount of gastric mucus by the extract of AJC in acute gastritis / gastric ulcer animal model induced by HCl / ethanol.
  • Figure 9 is a result confirming the effect of increasing the activity of the superoxide dismutase by AJC (AEAC) in acute gastritis / gastric ulcer animal model induced by HCl / ethanol.
  • AEAC superoxide dismutase
  • 11 is a result of confirming the effect of increasing the expression of gastric mucosa protein MUC5AC after a single administration of AJC (AEAC) in acute gastritis / gastric ulcer animal model induced by HCl / ethanol.
  • AEAC AJC
  • rPigr a mucosal immune-related factor after a single administration of AJC in acute gastritis / gastric ulcer animal model induced by HCl / ethanol.
  • Figure 13 is a result of confirming the effect of increasing the expression of TFF1, 2 and 3 involved in gastric mucosa protection and treatment after a single administration of AJC in acute gastritis / gastric ulcer animal model induced by HCl / ethanol.
  • 16 is a result of confirming the effect of increasing the expression of rPigr, gastric mucosal immunity-related factors after repeated administration of AJC in acute gastritis / gastric ulcer animal model induced by HCl / ethanol.
  • Figure 17 shows the effect of increasing the expression of TFF1, 2 and 3 involved in gastric mucosa protection and treatment after repeated administration of AJC in acute gastritis / gastric ulcer animal model induced by HCl / ethanol.
  • FIG. 18 is a method for protecting and treating gastric mucosa protein, gastric mucosal immunity related factors and gastric mucosa after repeated administration of AJC or licorice extract (AC) in HCl / ethanol-induced acute gastritis / gastric ulcer animal model This is the result of confirming the effect of increasing the expression of the factors involved.
  • AJC licorice extract
  • FIG. 19 is a photograph comparing the degree of gastric mucosal injury caused by dissecting the Taiwanese stomach after single administration of AJC or Licorice extract (AC) in acute gastritis / gastric ulcer animal model induced by HCl / ethanol. to be.
  • FIG. 20 is a quantitative analysis of gastric mucosal injury length caused by dissection of the Taiwanese stomach after single administration of AJC or Licorice Extract (AC) in acute gastritis / gastric ulcer animal model induced by HCl / ethanol. The result is.
  • Figure 21 is a photograph comparing the degree of gastric mucosal damage caused by dissection of the stomach part of the stomach after repeated administration of AJC or licorice extract (AC) in acute gastritis / gastric ulcer animal model induced by HCl / ethanol to be.
  • AJC licorice extract
  • Figure 23 is a photograph comparing the degree of damage caused by dissecting the stomach part of the stomach after a single administration of AJC or AEAA in acute gastritis / gastric ulcer animal model induced by HCl / ethanol.
  • TFF1 is not only known as a cancer suppressor gene in connection with gastric cancer, but has been reported to protect the gastrointestinal mucosa from various injuries, to stabilize the mucosal layer and to regulate the healing process of gastrointestinal epithelial tissue.
  • TFF2 has a function of inhibiting gastric acid secretion as well as a protective effect on the gastrointestinal mucosa of TFF1.
  • TFF3 is found not only in the gastrointestinal mucosa but also in breast milk and has been reported to exhibit excellent anti-inflammatory effects.
  • mucin proteins directly constitute the gastrointestinal mucosa and protect the gastrointestinal epithelial tissue
  • rPigr a mucosal immune-related factor
  • the Artemisia capillaris water-soluble extracts increase the expression of mucosal proteins or mucosal immune factors, specifically one or more mucosal proteins or mucosal immune factors selected from MUC5AC, MUC6, rPigr and TFF3, inflammatory Maintains and improves the homeostasis of the gastrointestinal mucosa system by inhibiting cytokine, inhibiting the production of lipid peroxides, or increasing antioxidant enzyme activity, and inhibiting inflammation and promoting mucosal production, thereby preventing or improving gastric mucosal damage.
  • the present invention has been completed by finding out.
  • the present invention is a water-soluble extract of Artemisia capillaris having an action of preventing or improving gastric mucosal gastrointestinal diseases, compositions and food compositions for preventing or ameliorating gastric mucosal gastrointestinal disorders, gastric mucosal gastrointestinal disorders It relates to a pharmaceutical composition for prophylaxis or treatment, and a method for preparing Artemisia capillaris water-soluble extract.
  • the first aspect of the present invention relates to a water-soluble extract of Artemisia capillaris having a prophylactic or ameliorating action of gastric mucosal damaging gastrointestinal diseases.
  • Artemisia capillaris water-soluble extract according to the present invention is extracted from hot water of Injin mugwort, mucosal proteins or mucosal immune factors, specifically MUC5AC, MUC6, rPigr, TFF1, TFF2 and TFF3 at least one protein or mucosal immunity It increases the expression of the factor, maintains and improves the homeostasis of the gastrointestinal tract mucosal system through inhibiting inflammatory cytokines, inhibiting the production of lipid peroxides or increasing antioxidant enzyme activity, and exhibits the effect of inhibiting inflammation or promoting mucosal production.
  • mucosal proteins or mucosal immune factors specifically MUC5AC, MUC6, rPigr, TFF1, TFF2 and TFF3 at least one protein or mucosal immunity It increases the expression of the factor, maintains and improves the homeostasis of the gastrointestinal tract mucosal system through inhibiting inflammatory cytokines, inhibiting the production of lipid peroxides or increasing
  • the Artemisia capillaris water-soluble extract of the present invention prevents or ameliorates mucosal damaging gastrointestinal disorders caused by, for example, gastric acid, ethanol, stress, or a combination thereof, gastric acid, ethanol, stress or a combination thereof. It can be used to prevent or inhibit the damage to the mucous membrane by gastritis or gastric ulcer caused by.
  • the second aspect of the present invention relates to a composition for the prevention or improvement of gastric mucosal damaging gastrointestinal disease containing the water extract of Artemisia capillaris .
  • a third aspect of the present invention relates to a food composition for preventing or ameliorating gastric mucosal damaging gastrointestinal disease containing the water extract of Artemisia capillaris .
  • a fourth aspect of the present invention relates to a pharmaceutical composition for the prevention or treatment of gastric mucosal damage gastrointestinal diseases containing Artemisia capillaris water-soluble extract.
  • the pharmaceutical composition for the prevention or treatment of gastric mucosal damaging gastrointestinal diseases contains a water-soluble extract of Artemisia capillaris as an active ingredient, specifically gastric mucosal proteins or mucosal immune factors, specifically MUC5AC, MUC6, rPigr, TFF1, Increases the expression of one or more gastric mucosal proteins or mucosal immune factors selected from TFF2 and TFF3, maintains and improves the homeostasis of the gastrointestinal mucosal system through inhibiting inflammatory cytokines, inhibiting the production of lipid peroxides or increasing antioxidant enzyme activity, Inhibit inflammation or promote mucosal production.
  • the pharmaceutical composition for preventing or treating gastric mucosal damaging gastrointestinal diseases may further include appropriate carriers, excipients, diluents, and the like commonly used in the preparation of pharmaceutical compositions in addition to the water-soluble extract of Artemisia capillaris . .
  • the pharmaceutical composition according to the present invention may contain the Artemisia capillaris water-soluble extract as it is or may contain a pharmaceutically acceptable salt of the components contained in the extract.
  • the pharmaceutical composition of the present invention may be used alone or in combination with other pharmaceutically active compounds of Artemisia capillaris .
  • compositions for the prevention or treatment of gastric mucosal injury gastrointestinal diseases according to the present invention, powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, external preparations, suppositories, according to conventional methods and needs It may be used in any form such as sterile injectable solution.
  • the fifth aspect of the present invention relates to a method for producing an aqueous extract of Artemisia capillaris .
  • step (1) 10-14 times of water, preferably purified water, is added to Artemisia capillaris , dried and cut to an appropriate size, preferably at 80 ⁇ 20 ° C, more preferably at 90 ⁇ 10 ° C. Extract for 3-5 hours. Therefore, the hydrothermal water of step (1) may be preferably 80 ⁇ 20 ° C., more preferably 90 ⁇ 10 ° C. water.
  • step (2) the extract obtained in step (1) is cooled to room temperature and then filtered, and the filtrate is concentrated under reduced pressure at a temperature of less than 60 ° C. first, and then centrifuged at 4000 to 7000 rpm or more, and the precipitate is Remove by filtration.
  • step (3) the concentrated solution from which the precipitate is removed is concentrated under a second reduced pressure until the water content is 55 ⁇ 5% at less than 60 ° C. to obtain a water-soluble extract of Insam.
  • Artemisia capillaris used as a raw material can be used as long as it is native to Korea.
  • RNA samples NaOH, methyl orange, calcium carbonate, hydrochloric acid, ethanol were purchased from Sigma-Aldrich (St. Louis, MO, USA).
  • Oligo (dT), dNTP, RNase-free water and Superscript III First-Strand Synthesis used in Polymerase chain reaction (PCR) analysis were purchased from Invitrogen (Carlsbad, CA, USA).
  • the RNeasy Mini Kit and Rotor-Gene SYBR Green PCR Kit were purchased from Qiagen (Valencia, CA, USA) and oligonucleotide primers were purchased from Bioneer (Daejeon, Korea).
  • HMC-1 Human Mast Cells (HMC-1) were purchased from the Bank of Korea Cell Line, and 10% fetal bovine serum (FBS), 100 U / ml penicillin and 100 ⁇ g / ml streptomycin (GibcoBRL, USA) Cultured under 37 ° C., 5% CO 2 environment with added IMDM medium (GibcoBRL, USA).
  • FBS fetal bovine serum
  • IMDM medium GibcoBRL, USA
  • RAW264.7 cells a mouse-derived macrophage line, were cultured in a 37 ° C., 5% CO 2 environment using DMEM medium supplemented with 10% fetal calf serum and 1% penicillin-streptomycin.
  • the concentrated solution from which the precipitate was removed was concentrated under a second reduced pressure until the moisture content was 55 ⁇ 5% at less than 60 ° C to obtain a water-soluble extract of AJU (AEAC, 45 ⁇ 5% solids), and 30-60 minutes at 85-90 ° C. Sterilized during.
  • the extract was packaged in a container and refrigerated and used as the final sample for this experiment (yield: 8-13% based on the solids content of AEAC relative to the weight of the raw material).
  • the content of scopoletin an index component of water soluble extracts, was analyzed by Dionex Chromelon TM Chromatography Data System at a wavelength of 344nm using a C18 column (4.6 ⁇ 250mm, 100 ⁇ , Kinetex). At this time, 0.05% formic acid aqueous solution was used as the A solvent and acetonitrile was used as the B solvent as the mobile phase. Analysis was carried out in mobile phase conditions of A / B (90/10), 13 min A / B (5/95), 16 min (Gradient) -A / B (90/10). As a result of HPLC analysis, the scopoletin content of the water-soluble extracts of the extract was averaged at 3.502 mg per g of the extract.
  • the antacid test is a test method for confirming the antacid power of an agent that reacts with gastric acid, and in the present invention, it was tested according to the antacid test method specified in the Korean Pharmacopoeia.
  • a mixture of licorice extract (AC) and leafy water soluble extract (AEAA), and the extract of AJC (AEAC) according to the present invention were mixed in 100 ml of 0.1 N HCl, and reacted for 1 hour in a shaking incubator at 37 ° C. After titration, the mixture was titrated with 0.1N NaOH. Methyl orange was used as an indicator and calcium carbonate was used as a positive control.
  • compound 48/80 (Sigma, USA), a potent drug that increases the infiltration of mast cells by increasing Ca 2+ influx into the cell membrane of mast cells, was used. After dispensing the cultured mast cells into a 24 well plate, each sample was pretreated for 2 hours at different concentrations, treated with Compound 48/80, and after 30 minutes, the supernatant was taken and secreted into the medium. The amount was measured.
  • the cytokine secretion of mast cells was induced by a combination of phorbol myristate acetate (PMA) and A23187. After the cultured mast cells were dispensed into 24 well plates, each sample was pretreated for 1 hour, and then treated with PMA and A23187. After 8 hours, supernatants or cells were taken and used for cytokine measurement.
  • PMA phorbol myristate acetate
  • Raw264.7 cells which are macrophages, were treated with LPS at a concentration of 1 ⁇ g / ml after pretreatment of each sample for 1 hour at concentration, and supernatants or cells were taken 24 hours later and used for cytokine measurement.
  • Cytokine measurements were performed according to the manufacturer's instructions by purchasing sandwich ELISA kits for IL-1 and IL-6.
  • the standard curve was calculated from the absorbance of standard and the amount of cytokine was quantified from the absorbance of each sample.
  • Qiagen's Rotor-Gene Q 2 plex real-time DNA amplifier and Qiagen's two step PCR SYBR kit were used to perform real-time polymerase chain reaction according to the manufacturer's instructions, and the amount of amplified DNA was quantitatively compared. Specifically, pre-denaturation was performed at 95 ° C. for 5 minutes based on a cycling protocol, followed by 40 cycles of 5 seconds at 95 ° C. and 10 seconds at 60 ° C. for 3 minutes from 60 ° C. to 95 ° C. It was performed in the order of the rising melting step. Products amplified by real-time polymerase chain reaction were quantified using the Delta delta Ct method and corrected by the expression level of GAPDH for each sample. The base sequence of the primers used in the experiment is as shown in the following [Table 1].
  • control group In the control group, the general formula, the positive control group, ranitidine or licorice extract, and the experimental group were orally administered AEAC. After 30 minutes, 1 mL of HCl-EtOH (60% EtOH containing 150 mM HCl) was orally administered to each of the control, positive control, and experimental groups.
  • HCl-EtOH 50% EtOH containing 150 mM HCl
  • mice Six male rats with a body weight of about 200 g were divided into three groups: a control group, a positive control group, and an experimental group.
  • control group was orally administered with the general formula, the positive control group with licorice extract, and the experimental group with AEAC twice a day for 1 week. Fasting for more than 24 hours after the last oral administration.
  • control group was administered with the general formula, the positive control group with the licorice extract and the experimental group with oral AEAC, and after 30 minutes, 1 mL of HCl-EtOH (60% EtOH containing 150 mM HCl) was orally administered to the control group, the positive control group, and the experimental group. It was.
  • Qiagen's Rotor-Gene Q 2 plex real-time DNA amplifier and Qiagen's two step PCR SYBR kit were used to perform real-time polymerase chain reaction according to the manufacturer's instructions, and the amount of amplified DNA was quantitatively compared. Specifically, pre-denaturation was performed at 95 ° C. for 5 minutes based on a cycling protocol, followed by 40 cycles of 5 seconds at 95 ° C. and 10 seconds at 60 ° C. for 3 minutes from 60 ° C. to 95 ° C. It was carried out in the order of the rising melting step. Products amplified by real-time polymerase chain reaction were quantified using Delta delta Ct method and corrected by the expression level of ⁇ -actin for each sample. The base sequence of the primers used in the experiment is as shown in the following [Table 2].
  • Malondialdehyde (MDA), a lipid peroxide, was measured using thiobarbituric acid reactive substances (TBARS) assay according to the method of Emerit et al. (Presse Med. 1986 Jun 14; 15 (24): 1131-3). .
  • Superoxide disproportionation enzyme (Superoxide dismutase; SOD) is a representative radical trapping the enzyme in the body, superoxide anion, which acts to return to;; (hydrogen peroxide H 2 O 2) ( ⁇ O2 superoxide anion) hydrogen peroxide It is known. Superoxide dismutase was measured using a SOD Assay Kit (Dojindo Molecular Technologies, USA).
  • the secretion of histamine in the mast cells induced by compound 48/80 was effectively reduced by curcumin, a positive control, while licorice extract (AC) or A. eryngii water-soluble extract (AEAC). As little changes in histamine levels were observed, water extract of A. erythema (AEAC) had no effect on degranulation inhibition of mast cells.
  • the secretion of inflammatory cytokines IL-1 ⁇ and IL-6 was significantly increased in LPS-induced macrophages, and the increase in inflammatory cytokines was markedly decreased by AJC. It confirmed that it became. In addition, it was confirmed that there is no difference in efficacy due to the change in formulation of the liquid or powder process.
  • leaf extract exhibits an antacid like the calcium carbonate.
  • Leafy leaf extract (AEAA) is thought to have the effect of temporarily preventing gastric damage by acid through neutralization reaction.
  • no neutralization-related functions were observed in the water extract of AJU (AEAC) and licorice extract (AC), which means that there are no side effects such as excessive secretion of gastric acid due to a simple neutralization reaction.
  • the licorice extract (AC) of 100 mg / kg was 98.7% compared to the HCl / ethanol-administered group.
  • the same dose of A. eryngii water extract (AEAC) showed a 104.2% increase, showing a slightly higher gastric mucus increase effect than licorice extract (AC).
  • the water extract of A. erythema (AEAC) showed the effect of increasing the amount of gastric mucus in a dose-dependent manner, and showed the maximum effect at the highest dose of 400 mg / kg. It was confirmed that the protective effect against / ethanol-induced acute gastritis / gastric ulcer.
  • the treatment and defense effect of AUGC in the acute gastritis / gastric ulcer animal model shows the inflammatory treatment effect by restoring the gastric mucosa's defense function which is reduced by inflammation by restoring SOD activity, an antioxidant enzyme.
  • gastric mucosa protein MUC6 when repeated administration of 200 mg / kg or 400 mg / kg of agar water soluble extract (AEAC), gastric mucosa protein MUC6 is 2.4 to 3.9 times, MUC5AC compared to the case of administration only HCl / ethanol was increased 3.0-4.6 fold, rPigr, a factor related to gastric mucosal immunity, 3.9-4.3 fold, TFF1 2.5-4.1 fold, TFF2 9.4-18.2 fold, TFF3 3.2- 4.2 fold.
  • AEAC agar water soluble extract
  • the water extract of A. eryngii (AEAC) according to the present invention directly promotes the production of mucosal proteins, and it can be seen that it has a continuous gastric mucosal protection effect.
  • the mucosal protein system seems to have a protective effect on the gastrointestinal mucosa due to the increase of TFF2, as well as a symptom improvement effect by suppressing gastric acid secretion.
  • the gastric injury inhibition rate was 100% inhibition in both 200 mg / kg and 400 mg / kg administration groups when HJ / ethanol was administered followed by administration of AJC.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Botany (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne un extrait soluble dans l'eau de l'Artemisia capillaris ayant un effet de prévention ou de soulagement de maladies gastro-intestinales blessées la muqueuse gastrique, et une composition pour prévenir ou soulager des maladies gastro-intestinales blessées les muqueuses, contenant celui-ci et, plus spécifiquement, à une composition, une composition alimentaire, et une composition pharmaceutique pour prévenir ou soulager des maladies gastro-intestinales blessées les muqueuses, toutes les compositions ayant un effet pour prévenir ou soulager des maladies gastro-intestinales blessées les muqueuses provoquées par un excès d'acide gastrique, de l'alcool, du stress, etc. par l'entretien, la protection et la régénération du système muqueux gastro-intestinal.
PCT/KR2017/014030 2016-12-01 2017-12-01 Extrait soluble dans l'eau de l'artemisia capillaris, son utilisation et son procédé de préparation WO2018101798A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160162640A KR20180062682A (ko) 2016-12-01 2016-12-01 인진쑥 수용성 추출물, 그 용도 및 제조 방법
KR10-2016-0162640 2016-12-01

Publications (1)

Publication Number Publication Date
WO2018101798A1 true WO2018101798A1 (fr) 2018-06-07

Family

ID=62242170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/014030 WO2018101798A1 (fr) 2016-12-01 2017-12-01 Extrait soluble dans l'eau de l'artemisia capillaris, son utilisation et son procédé de préparation

Country Status (2)

Country Link
KR (1) KR20180062682A (fr)
WO (1) WO2018101798A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102405386B1 (ko) 2019-12-18 2022-06-08 (주)에스디생명공학 바다제비집 복합추출물을 유효성분으로 포함하는 면역증진용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020035322A (ko) * 2000-11-06 2002-05-11 안용찬 쑥 추출물을 함유하는 아토피성 피부용 화장료 조성물
KR20140068831A (ko) * 2014-05-09 2014-06-09 주식회사 엘지생활건강 주름개선용 화장료 조성물
KR20150055667A (ko) * 2013-11-13 2015-05-22 주식회사 케이스템셀 사철쑥 유래 스코파론 함유 추출물을 유효성분으로 포함하는 골다공증 예방 또는 치료용 조성물
KR20160008100A (ko) * 2014-06-30 2016-01-21 명지대학교 산학협력단 인진쑥 추출물 또는 이의 분획물을 유효성분으로 함유하는 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08295632A (ja) 1995-03-02 1996-11-12 Takeda Chem Ind Ltd 抗菌剤
KR100379189B1 (ko) 2000-12-14 2003-04-08 학교법인고려중앙학원 헬리코박터 파이로리에 의한 위질환 치료제용 조성물 및그 탐색방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020035322A (ko) * 2000-11-06 2002-05-11 안용찬 쑥 추출물을 함유하는 아토피성 피부용 화장료 조성물
KR20150055667A (ko) * 2013-11-13 2015-05-22 주식회사 케이스템셀 사철쑥 유래 스코파론 함유 추출물을 유효성분으로 포함하는 골다공증 예방 또는 치료용 조성물
KR20140068831A (ko) * 2014-05-09 2014-06-09 주식회사 엘지생활건강 주름개선용 화장료 조성물
KR20160008100A (ko) * 2014-06-30 2016-01-21 명지대학교 산학협력단 인진쑥 추출물 또는 이의 분획물을 유효성분으로 함유하는 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PARK, J.-M. ET AL: "The anti-inflammatory effects of acidic polysaccharide from Artemisia capillaris on Helicobacter pylori infection", JOURNAL OF CANCER PREVENTION, vol. 18, no. 2, 2013, pages 161 - 168, XP055606894 *

Also Published As

Publication number Publication date
KR20180062682A (ko) 2018-06-11

Similar Documents

Publication Publication Date Title
WO2012070890A2 (fr) Composition pharmaceutique comportant un extrait de lonicera japonica pour prévenir et traiter le reflux gastro-oesophagien pathologique
WO2010147440A2 (fr) Aliment de santé ou composition pharmaceutique comprenant un extrait de bogue de châtaigne
WO2011149301A2 (fr) Composition comprenant l'extrait de physalis alkekengi var. francheti hort en tant que principe actif pour la prévention et le traitement de maladies inflammatoires
WO2015111832A1 (fr) Composition de prévention ou de traitement de maladies liées à la prostate, contenant un extrait de poncirus trifoliata
WO2018101798A1 (fr) Extrait soluble dans l'eau de l'artemisia capillaris, son utilisation et son procédé de préparation
WO2017150934A1 (fr) Composition comprenant de la panduratine ou un extrait de curcuma rond (boesenbergia pandurata) pour le traitement, la prévention ou l'amélioration d'une maladie de perte osseuse
WO2020032365A1 (fr) Composition, comprenant un composé de ginsénoside, pour la prévention ou le traitement d'une maladie inflammatoire médiée par des inflammasomes
WO2019177428A1 (fr) Composition de matière première de médicament pour prévenir ou traiter des maladies respiratoires
WO2010123221A9 (fr) Composition de prévention et d'amélioration des symptômes de la ménopause contenant des glycéollines comme principe actif
WO2021080388A1 (fr) Composition pour prévenir ou traiter l'infection par le virus de la diarrhée épidémique porcine, comprenant un complexe contenant un composé à base de curcuminoïde et un extrait de réglisse ou une fraction de celui-ci
WO2016010340A1 (fr) Composition pour prévenir et traiter l'inflammation ou les maladies allergiques contenant un extrait de gynura procumbens en tant que principe actif, et son utilisation
WO2024005561A1 (fr) Composition comprenant un extrait de stewartia pseudocamellia en tant que principe actif pour la prévention ou le traitement de la démence
WO2014042426A1 (fr) Composition comprenant de la saikosaponine a, de la berbérine et de la licoisoflavone b pour la prévention ou le traitement de maladies gastriques
WO2013122344A1 (fr) Composition pharmaceutique contenant en tant qu'ingrédient actif un extrait provenant de l'écorce de liriodendron tulipifera
KR20200101898A (ko) 인진쑥 수용성 추출물, 그 용도 및 제조 방법
WO2018106002A1 (fr) Composition pour la prévention et le traitement de la stérilité masculine, contenant une combinaison de composés comprenant un dérivé de flavonoïde et un dérivé d'iridoïde à titre de principe actif, et son utilisation
WO2022139529A1 (fr) Composition pour la prévention, l'amélioration ou le traitement de la gastrite ou de l'ulcère gastroduodénal comprenant un extrait de cinnamomum cassia, une fraction dudit extrait, un isolat de ladite fraction ou des composés isolés à partir de ladite fraction
WO2016032250A1 (fr) Composition pharmaceutique contenant un extrait de portulaca grandiflora hook. ou une fraction de celui-ci comme principe actif pour prévenir ou traiter une inflammation des nerfs ou des maladies neurodégénératives
WO2016144125A2 (fr) Nouvelle utilisation d'extrait de solanum nigrum l.
WO2013024960A1 (fr) Composition médicale contenant un extrait de stauntonia hexaphylla
WO2021033995A1 (fr) Composition comprenant un extrait d'amomum tsaoko pour prévenir, atténuer ou traiter une maladie liée à la sarcopénie
KR20180082921A (ko) 위염 또는 소화성궤양 예방 또는 치료용 조성물
WO2014126269A1 (fr) Composition pharmaceutique pour améliorer la fonction sexuelle masculine et pour traiter l'infertilité
WO2020004989A1 (fr) Composition pour la prévention, l'amélioration ou le traitement de la cachexie comprenant du kimchi
WO2023085820A2 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies musculaires

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17876705

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17876705

Country of ref document: EP

Kind code of ref document: A1